Regulation of Brain Gene Therapy Research Governance in China

1. Introduction

Brain gene therapy involves the introduction, modification, or regulation of genetic material in cells of the brain or central nervous system to treat neurological disorders. It may use viral vectors, gene-editing technologies such as CRISPR-Cas systems, or other genetic delivery platforms to address conditions such as Parkinson’s disease, inherited neurological disorders, and certain forms of epilepsy.

In China, brain gene therapy research is governed by a combination of biotechnology regulations, clinical-trial rules, ethical-review requirements, human genetic resources legislation, and biosecurity controls. The regulatory framework aims to protect research participants, ensure scientific reliability, prevent genetic-data misuse, and maintain oversight of potentially irreversible interventions.

An important distinction: China does not rely on a single statute exclusively devoted to brain gene therapy. Instead, the applicable requirements depend on whether the activity is laboratory research, animal experimentation, a clinical trial, or an intervention involving human germline cells. Research involving somatic brain cells must also be distinguished from heritable genetic modification.

2. Principal Legal and Regulatory Framework

A. Biosecurity Law of the People’s Republic of China, 2021

China’s Biosecurity Law establishes a broad framework for managing biological risks associated with biotechnology research and development. It addresses biotechnology research, pathogenic microorganisms, human genetic resources, and other activities capable of creating biological-security risks.

For brain gene therapy, the law is relevant where research involves potentially hazardous biological materials, genetically modified biological agents, or activities subject to national biosecurity assessment and supervision.

Research institutions are expected to identify relevant risks, maintain appropriate safety-management systems, and comply with applicable approval, reporting, and supervision requirements. The law does not, however, automatically require every brain gene therapy experiment to undergo the same national-level review. The precise obligation depends on the research materials, procedures, and applicable implementing rules.

B. Regulations on the Administration of Human Genetic Resources, 2019, as amended

China’s human genetic resources framework regulates the collection, preservation, use, and international provision of human genetic resources and associated information.

Brain gene therapy research may involve blood samples, tissue specimens, genomic sequences, or other materials obtained from patients. Where these fall within the statutory definition of human genetic resources, the relevant requirements must be considered.

The principal concerns include:

Lawful collection and use of human biological materials.

Protection of participants’ interests and privacy.

Compliance with applicable requirements for international collaboration.

Regulation of the provision of human genetic resource information to foreign organizations or individuals.

The rules are especially important when a Chinese hospital collaborates with a foreign university, biotechnology company, or international research consortium. The legal classification of the material and the nature of the collaboration determine the applicable procedures.

C. Drug Administration Law and Clinical-Trial Regulations

The Drug Administration Law, revised in 2019, and the applicable drug-registration framework govern investigational products intended for therapeutic use. Biological products, including many gene therapy products, may fall within these requirements.

Where a brain gene therapy product is developed for clinical use, the sponsor must determine whether an investigational drug application and regulatory authorization are required before the trial begins.

The China National Medical Products Administration (NMPA) and its relevant technical bodies play central roles in the drug-development and clinical-trial framework. Requirements may include preclinical safety evidence, manufacturing-quality controls, trial protocols, adverse-event reporting, and regulatory review.

A hospital’s ethical approval alone does not replace a regulatory authorization required for an investigational product.

D. Regulation on the Clinical Research and Translational Application Management of New Biomedical Technologies, 2026

A major development is State Council Order No. 818, which took effect on 1 May 2026. It establishes a statutory framework for clinical research and clinical translation of new biomedical technologies, including qualifying interventions involving human cells and molecular processes.

xzfg.moj.gov.cn

+1

Under Articles 8–19, the framework provides for preclinical evidence, institutional qualifications, academic and ethical review, filing, informed consent, and continuing supervision. Clinical research institutions must satisfy prescribed requirements, including the required institutional committees and research capacity.

Articles 29–34 establish a separate approval process for translating covered technologies into clinical practice. Thus, permission to conduct research does not itself authorize routine therapeutic use.

For brain gene therapy, the first question is whether the proposed intervention falls under this biomedical-technology framework or the drug-registration system. The legal classification matters because the competent authority and approval pathway differ.

3. Ethical Review and Protection of Participants

China’s Regulation on the Administration of Ethical Review of Life Science and Medical Research Involving Humans, 2023, provides another important layer of governance. Research involving human participants must undergo the applicable ethical review before commencement.

An ethics committee should consider:

Whether the scientific objectives justify the foreseeable risks.

Whether participants receive adequate information and provide voluntary consent.

Whether vulnerable participants receive additional protection.

Whether privacy, genetic information, and biological samples are appropriately protected.

Whether adverse events, protocol amendments, and emerging risks are monitored.

Brain gene therapy raises particularly serious ethical concerns because genetic interventions may produce long-lasting effects that cannot readily be reversed. Researchers must also address uncertainty concerning off-target effects, immune reactions, neurological injury, and delayed complications.

Where a participant lacks legal capacity, the applicable consent and representation rules must be followed. The 2026 biomedical-technology regulation expressly requires written informed consent and prohibits obtaining it through deception, coercion, or inducement.

中华人民共和国国家卫生健康委员会

+1

4. Relevant Case Laws and Legal Precedents

A. People v. He Jiankui (Shenzhen, 2019)

The most significant Chinese criminal precedent involving human gene editing concerns He Jiankui, who announced the birth of genetically edited children in 2018.

In December 2019, a court in Shenzhen convicted He of illegal medical practice. He received a three-year prison sentence and a fine. Two collaborators also received criminal penalties.

The court found that the defendants had violated applicable state regulations and ethical requirements by organizing reproductive gene-editing activities without the required qualifications and approvals.

Legal significance: Although this case concerned germline editing rather than therapeutic modification of brain cells, it demonstrates that scientific novelty does not exempt researchers from professional licensing, ethical oversight, and legal authorization requirements. It also illustrates the potential criminal consequences of unauthorized human genetic interventions.

B. He Jiankui and the Biosecurity Law framework

The Biosecurity Law, particularly Articles 34–36, requires ethical compliance, institutional responsibility for biological risks, and risk-based management of biotechnology research. Article 40 addresses clinical research on new biomedical technologies.

NPC

The He Jiankui proceedings provide a relevant enforcement precedent, but they should not be described as a judicial ruling directly interpreting every provision of the later Biosecurity Law or the 2026 regulation. Their relevance lies principally in the enforcement of existing medical and ethical restrictions.

C. Absence of a directly controlling brain-gene-therapy judgment

The above precedents do not establish a reported Chinese judgment specifically deciding the legality of a brain gene therapy clinical trial. Their application to neurological gene therapy is therefore analogical, supported by the relevant statutes and regulatory framework rather than a direct judicial holding on that precise technology.

5. Clinical Trial Monitoring and Institutional Accountability

Clinical trials involving gene therapy products regulated as drugs must comply with applicable NMPA requirements and Good Clinical Practice. China’s revised GCP rules, effective 1 September 2026, incorporate ICH E6(R3) principles. These rules reinforce trial quality, participant protection, documentation, and safety monitoring.

ClinRegs

+1

Sponsors and investigators should establish procedures for adverse-event reporting, long-term follow-up where scientifically justified, data integrity, and the investigation of suspected treatment-related neurological complications. Serious safety concerns may require suspension or modification of a trial.

6. Conclusion

China governs brain gene therapy research through a combination of biosecurity legislation, human genetic resources rules, ethical-review requirements, drug regulation, and the 2026 framework for new biomedical technologies. The central legal distinction is between authorized research and approved clinical application.

The He Jiankui case demonstrates the consequences of bypassing legal and ethical safeguards, although it is not a direct brain gene therapy precedent. Ultimately, any proposed neurological gene therapy must be assessed according to its technical characteristics, risk profile, institutional setting, and regulatory classification.